NCT07470489 2026-04-16
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
21 trialsNCT07527325 2026-04-14
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
University of California, Irvine
Phase 2 Not yet recruiting
NCT07422363 2026-04-13
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07511036 2026-04-06
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT06943664 2026-03-24
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
NCT07281768 2026-03-20
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT07179315 2026-03-04
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
University of Chicago
Phase 2 Not yet recruiting
NCT07450183 2026-03-04
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
Henry Ford Health System
Phase 2 Not yet recruiting
NCT07418931 2026-02-18
CECYDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT07414992 2026-02-17
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Not yet recruiting
NCT07234058 2026-02-11
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT07360743 2026-02-10
META-1
UNICANCER
Phase 2 Not yet recruiting
NCT07224022 2026-02-04
NACho
Duke University
Phase 2 Not yet recruiting
NCT07387198 2026-02-04
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Not yet recruiting
NCT07346196 2026-01-20
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
University of Chicago
Phase 2 Not yet recruiting
NCT07274384 2025-12-10
HYPERBOLIC
Università Vita-Salute San Raffaele
Phase 2 Not yet recruiting
NCT07101822 2025-08-03
BRAVA PENILE
Hospital Israelita Albert Einstein
Phase 2 Not yet recruiting
NCT07101848 2025-08-03
BRAVA VULVAR
Hospital Israelita Albert Einstein
Phase 2 Not yet recruiting
NCT07058012 2025-07-10
EMPIRE
NSABP Foundation Inc
Phase 2 Not yet recruiting
NCT06743581 2024-12-20
Dupi-Cemi
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Not yet recruiting